503A vs 503B compounded semaglutide: the difference that affects your safety
Two legal compounding categories hide behind one word. What separates them, why the resolved shortage narrowed the rules, and how to verify your source.
Two legal categories, one confusing label
"Compounded" hides a distinction that materially affects oversight. Under the Federal Food, Drug, and Cosmetic Act, compounding lives in two sections. Section 503A covers traditional pharmacy compounding: a licensed pharmacist prepares a medication for an individual patient pursuant to a valid prescription. Section 503B covers outsourcing facilities, which voluntarily register with the FDA, submit to federal inspection, and must follow Current Good Manufacturing Practice (CGMP) — the same quality framework governing conventional drug manufacturing.
The differences that actually matter
| Attribute | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Basis | Individual prescription | Batch, with/without individual scripts |
| FDA registration | State-board licensed | Registers with and inspected by FDA |
| Manufacturing standard | USP compounding standards | CGMP (federal) |
| Batch/stability testing | Variable | More systematic |
| Personalization | High | Lower |
| FDA-approved product? | No | No |
Why the shortage resolution changed everything
During the semaglutide shortage, compounders could produce copies of the commercial drug under shortage provisions, and cheap compounded semaglutide flooded the telehealth market. When the FDA declared the shortage resolved, that broad allowance narrowed: routine copying of the approved product is no longer permitted, and programs generally must rely on clinical-customization pathways. This is the regulatory event behind the market consolidation we track and the reason provider transparency now matters more than price.
What to verify before you pay
Whichever category a program uses, the trust move is the same: make them name the pharmacy before payment, then verify it. For a 503A, check the state board of pharmacy license; for a 503B, confirm the facility on the FDA's registered-outsourcing-facility list. A program that won't disclose its pharmacy is the single biggest red flag in our red-flags framework.
How to read a provider's pharmacy disclosure
Once you understand the 503A/503B distinction, the next skill is reading what a program actually tells you — and what it conspicuously doesn't. Transparent programs name their pharmacy partner outright, often stating whether it's a 503A compounding pharmacy or a 503B outsourcing facility, and provide enough detail to verify the claim independently. Vaguer language ("our licensed partner pharmacies," "US-based compounding") without a name is a signal to slow down and ask directly before paying.
The verification itself is quick. For a named 503A pharmacy, the state board of pharmacy's online license lookup confirms it's licensed and in good standing in the state where it operates. For a 503B facility, the FDA publishes a current list of registered outsourcing facilities you can search by name. Platform-level certification from LegitScript is an additional positive signal, indicating the telehealth service has passed a third-party legitimacy review. None of these steps require special expertise, and a legitimate program has no reason to make them difficult.
What you're really testing is willingness to be accountable. A pharmacy that stands behind its product will tell you who makes it; the finished compounded product still isn't FDA-approved either way, but a named, verifiable, appropriately-registered pharmacy with genuine clinical oversight is a categorically different proposition from an anonymous fulfillment chain. This is why, in our scoring, pharmacy transparency carries heavy weight and refusal to disclose is disqualifying regardless of how attractive the price looks. Price tells you what you'll pay; disclosure tells you what you're actually buying.
Frequently asked questions
What is the difference between 503A and 503B compounding?
503A is traditional pharmacy compounding for an individual patient against a prescription under USP standards. 503B outsourcing facilities register with and are inspected by the FDA, follow CGMP standards, and can produce batches. 503B carries more federal oversight; 503A allows more personalization. Neither is FDA-approved.
Is 503B compounded semaglutide safer than 503A?
503B facilities operate under CGMP and FDA inspection, which many clinicians view as stronger manufacturing oversight for injectables. 'Safer' still depends on the specific pharmacy. The key protection either way is a named, verifiable pharmacy with genuine clinical oversight.
Can compounded semaglutide still be made after the shortage ended?
Yes, but under narrower circumstances. With the shortage resolved, routine copying of the approved product is no longer permitted; programs generally rely on clinically personalized formulations.
How do I verify a compounding pharmacy?
For a 503A, verify the license through the state board of pharmacy. For a 503B, confirm the facility on the FDA's registered outsourcing facility list. Always ask the program to name its pharmacy before you pay; refusal is a major red flag.
References
- U.S. FDA. Compounding and the FDA: sections 503A and 503B.
- U.S. FDA. Registered Outsourcing Facilities (503B) list.
- U.S. FDA. Updates on semaglutide shortage status and compounding.
- Semaglutide Price Guide provider red-flags guide, July 2026.
Clinical figures from published trials and FDA labeling; pricing from provider-advertised rates checked July 2026 and subject to change. Educational, not medical or financial advice.